In short
A groundbreaking clinical trial is underway to assess the safety and effectiveness of AGTC-501, an innovative gene therapy for X-linked Retinitis Pigmentosa (XLRP). This study aims to evaluate the potential of a single subretinal injection of AGTC-501 in improving visual function for male participants with XLRP caused by mutations in the RPGR gene. The trial compares two doses of the therapy against an untreated control group, offering hope for those affected by this rare genetic eye disorder.
At a glance
- Study Type
- Phase III, randomized, controlled, masked, multi-center
- Intervention
- AGTC-501 (adeno-associated virus vector containing human RPGR gene)
- Target Population
- Males aged 12-50 with X-linked Retinitis Pigmentosa due to RPGR mutations
- Primary Outcome
- Change in retinal sensitivity at 12 months (measured by microperimetry)
- Key Secondary Outcomes
- Mobility test scores, visual acuity, full-field stimulus threshold, quality of life
- Treatment Administration
- Single subretinal injection
- Follow-up Duration
- At least 24 months
- Safety Monitoring
- Ocular and non-ocular adverse events
What is AGTC-501?
AGTC-501, also known by its scientific name laruparetigene zovaparvovec or rAAV2tYF-GRK1-RPGR, is an innovative gene therapy designed to treat a specific type of inherited eye disease. This therapy is currently being studied in clinical trials to evaluate its safety and effectiveness in treating X-linked retinitis pigmentosa (XLRP), a rare genetic condition that causes progressive vision loss, primarily affecting males.
How Does AGTC-501 Work?
AGTC-501 is a gene therapy that uses a modified virus to deliver a healthy copy of the RPGR gene to the retina. Here's a simplified explanation of how it works:
- The therapy is made using a harmless virus called adeno-associated virus (AAV).
- This virus is modified to carry a healthy copy of the RPGR gene, which is faulty in people with XLRP.
- The modified virus is injected directly under the retina in a procedure called a subretinal injection.
- Once in the eye, the virus delivers the healthy RPGR gene to the retinal cells.
- These cells can then use the healthy gene to produce the correct protein, potentially slowing or stopping vision loss.
Target Condition: X-Linked Retinitis Pigmentosa
X-linked retinitis pigmentosa (XLRP) is a genetic eye disorder that causes progressive vision loss. It primarily affects males because the faulty gene is located on the X chromosome. Symptoms typically begin in childhood and include:
- Night blindness (difficulty seeing in low light)
- Loss of peripheral (side) vision
- Eventual loss of central vision
Currently, there is no cure for XLRP, which is why gene therapies like AGTC-501 are being developed and studied.
Clinical Trial Details
AGTC-501 is being evaluated in a Phase III clinical trial. This is an advanced stage of research that aims to confirm the therapy's effectiveness and safety in a larger group of patients. Key details of the trial include:
- It's a randomized, controlled, and masked study, meaning participants are randomly assigned to receive either the treatment or no treatment, and neither the participants nor some of the researchers know who is in which group.
- The study is testing two different doses of AGTC-501.
- The main goal is to see if AGTC-501 can improve vision as measured by a special test called MAIA microperimetry, which assesses retinal sensitivity.
Eligibility Criteria
The clinical trial has specific criteria for who can participate. Some key eligibility requirements include:
- Male participants aged 12 to 50 years
- Confirmed diagnosis of XLRP with a documented mutation in the RPGR gene
- Specific levels of visual acuity and retinal sensitivity
- No previous gene therapy treatments
- No other significant eye conditions that could interfere with the study
Potential Benefits
If successful, AGTC-501 could potentially:
- Slow or stop the progression of vision loss in people with XLRP
- Improve retinal sensitivity and visual function
- Enhance the ability to see in low light conditions
- Improve overall quality of life for individuals with this condition
Safety Considerations
As with any medical treatment, there are potential risks and side effects to consider. The clinical trial is closely monitoring participants for any adverse events related to the treatment. Some potential risks may include:
- Reactions to the surgical procedure used to administer the therapy
- Immune system responses to the viral vector
- Potential side effects from medications used during and after the procedure
It's important to note that the safety of AGTC-501 is still being evaluated in the clinical trial.